...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Laryngoscope: A Medical Journal for Clinical and Research Contributions in Otolaryngology, Head and Neck Medicine and Surgery, Facial Plastic and Reconstructive Surgery .. >A novel drug therapy for recurrent laryngeal nerve injury using T-588.
【24h】

A novel drug therapy for recurrent laryngeal nerve injury using T-588.

机译：使用T-588的喉返神经损伤的新型药物疗法。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

OBJECTIVES/HYPOTHESIS: We have previously shown that gene therapy using Insulin-like growth factor (IGF)-I, glial cell line-derived neurotrophic factor (GDNF), and brain-derived neurotrophic factor (BDNF), or a combination of these trophic factors, is a treatment option for recurrent laryngeal nerve (RLN) palsy. However, there remain some difficulties preventing this option from becoming a common clinical therapy for RLN injury. Thus, we need to develop novel treatment option that overcomes the problems of gene therapy.R(-)-1-(benzothiophen-5-yl)-2-[2-N,N-diethylamino]ethoxy]ethanol hydrochloride (T-588), a synthetic compound, is known to have neuroprotective effects on neural cells. In the present study, the possibility of new drug treatments using T-588 for RLN injury was assessed using rat models. STUDY DESIGN: Animal study. METHODS: Animals were administered T-588 for 4 weeks. The neuroprotective effects of T-588 administration after vagal nerve avulsion and neurofunctional recovery after recurrentlaryngeal nerve crush were studied using motoneuron cell counting, evaluation of choline acetyltransferase immunoreactivity, the electrophysiologic examination, and the re-mobilization of the vocal fold. RESULTS: T-588 administration successfully prevented motoneuron loss and ameliorated the choline acetyltransferase immunoreactivity in the ipsilateral nucleus ambiguus after vagal nerve avulsion. Significant improvements of motor nerve conduction velocity of the RLN and vocal fold movement were observed in the treatment group when compared to controls. CONCLUSION: These results indicate that oral administration of T-588 might be a promising therapeutic option in treating peripheral nerve injury.
机译：目的/假设：我们先前已经证明了使用胰岛素样生长因子（IGF）-I，神经胶质细胞系神经营养因子（GDNF）和脑源性神经营养因子（BDNF）或这些营养结合的基因疗法因素，是喉返神经麻痹的一种治疗选择。但是，仍然存在一些困难，难以阻止这种选择成为RLN损伤的常见临床疗法。因此，我们需要开发克服基因治疗问题的新的治疗选择。R（-）-1-（苯并噻吩-5-基）-2- [2-N，N-二乙基氨基]乙氧基]乙醇盐酸盐（T- 588）是一种合成化合物，已知对神经细胞具有神经保护作用。在本研究中，使用大鼠模型评估了使用T-588治疗RLN损伤的新药的可能性。研究设计：动物研究。方法：给动物施用T-588，持续4周。使用运动神经元细胞计数，胆碱乙酰转移酶免疫反应性评估，电生理检查和声带复动，研究迷走神经撕脱伤后T-588给药和喉返神经挤压后神经功能恢复的神经保护作用。结果：T-588给药成功预防了运动神经元的丢失，并改善了迷走神经撕脱术后同侧核中胆碱乙酰转移酶的免疫反应性。与对照组相比，在治疗组中观察到RLN的运动神经传导速度和声带运动明显改善。结论：这些结果表明口服T-588可能是治疗周围神经损伤的有前途的治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号